Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice

URN to cite this document:: urn:nbn:de:bvb:355-epub-589113
DOI to cite this document:: 10.5283/epub.58911

Chennamsetty, Indumathi ; Kostner, Karam M. ; Claudel, Thierry ; Vinod, Manjula ; Frank, Sasa ; Weiss, Thomas S.

; Trauner, Michael ; Kostner, Gerhard M.

License: Creative Commons Attribution 4.0
PDF - Published Version
(617kB)

Date of publication of this fulltext: 16 Aug 2024 09:34

Alternative links to fulltext:DOI DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Elevated plasma lipoprotein(a) (LPA) levels are recognized as an independent risk factor for cardiovascular diseases. Our knowledge on LPA metabolism is incomplete, which makes it difficult to develop LPA-lowering medications. Nicotinic acid (NA) is the main drug recommended for the treatment of patients with increased plasma LPA concentrations. The mechanism of NA in lowering LPA is virtually ...